Acadia Healthcare Company, Inc. (ACHC) Stock Price & Analysis
Acadia Healthcare Company, Inc. (ACHC) closed at USD 31.88 on Thursday, October 22, 2026, up 1.43% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 31.43; the Oct 22, 2026 session ranged USD 31.05–32.2 on volume of 1,263,788 shares. Market capitalization is $2.97B, with a 52-week range of USD 11.43–35.83 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ACHC.md
Key facts (ACHC)
- Last four reported quarters (through Jun 30, 2026): revenue $3.37B, net income -$1.13B (-33.4% margin), free cash flow -$134M (SEC filings).
- 2 of 80 tracked superinvestors hold ACHC (13F, Q2 2026): 0 new, 0 added, 2 reduced, 0 unchanged.
- Analysts: Buy (mean 2.43 on a 1–5 scale) (14 analysts), mean target USD 33.79 (range 17–41).
- Total return with dividends: 1Y +35.7% vs S&P 500 +14.9%; 5Y -44.8% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 0.46, revenue estimate $878M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ACHC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.31B | $2.61B | $2.93B | $3.15B | $3.31B | $3.37B |
| Net income | $191M | $273M | -$21.7M | $256M | -$1.10B | -$1.13B |
| EPS (diluted) | $2.10 | $2.98 | -$0.24 | $2.78 | -$12.16 | — |
| Free cash flow | $130M | $84.4M | $38.2M | -$561M | -$440M | -$134M |
| Net margin | 8.2% | 10.5% | -0.7% | 8.1% | -33.3% | -33.4% |
| Revenue growth | +10.7% | +12.8% | +12.2% | +7.7% | +5.0% | — |
| Cash + short-term investments | $134M | $97.6M | $100M | $76.3M | $133M | — |
| Total debt | $1.50B | $1.39B | $1.37B | $1.96B | $2.50B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ACHC)
P/S 0.9x · EV/Sales 1.6x · P/B 1.5x · FCF yield -4.52% · Earnings yield -37.95% · Net debt $2.24B · EV $5.21B
P/E at fiscal year-ends: Dec 2024 14.3x.
Superinvestors (SEC 13F-HR, Q2 2026) (ACHC)
2 of 80 tracked investors hold ACHC. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Abrams Bison Investments, LLC | 6.00% | $123M | Reduced -4.9% | |
| David Einhorn | Greenlight Capital | 3.32% | $130M | Reduced -2.6% |
Analysts (ACHC)
Consensus Buy (mean 2.43 on a 1–5 scale), 14 analysts; mean target USD 33.79 (low 17, high 41).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | Leerink Partners | Target raised | Market Perform | $30 → $33 |
| 2026-07-30 | Guggenheim | Target raised | Buy | $38 → $39 |
| 2026-07-30 | Barclays | Target raised | Equal-Weight | $25 → $32 |
| 2026-07-20 | Guggenheim | Target raised | Buy | $31 → $38 |
| 2026-07-14 | TD Cowen | Target raised | Buy | $30 → $36 |
| 2026-07-14 | Keybanc | Target raised | Overweight | $30 → $40 |
| 2026-07-09 | UBS | Target raised | Buy | $31 → $39 |
Total return (dividends reinvested) (ACHC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +35.7% | -44.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +35.8% | -11.2% |
| Volatility (annualized) | 64.1% | 47.6% |
| Max drawdown | -50.3% (Oct 2025→Jan 2026) | -86.6% (Nov 2022→Jan 2026) |
ACHC revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Acute Inpatient Psychiatric Facilities | $494.6M | 57.1% | -0.2% |
| Comprehensive Treatment Centers | $141.2M | 16.3% | -0.2% |
| Specialty Treatment Facilities | $133.5M | 15.4% | -8.4% |
| Residential Treatment Centers | $96.6M | 11.2% | +11.6% |
| Total revenue | $865.8M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ACHC suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Ford (F) | “The five joint venture facilities opened during the year ended December 31, 2025, were through partnerships with Henry Ford Health, Geisinger Health, Ascension Seton, Fairview Health Services, and ECU Health.” |
Quoted from the company's 10-K filed Feb 27, 2026.
ACHC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.46 | $0.48 | -3.9% | $877.8M | 12 |
| Next quarter (ends Dec 2026) | $0.33 | $0.30 | +9.4% | $855.6M | 12 |
| Current fiscal year (ends Dec 2026) | $1.55 | $1.52 | +2.4% | $3.43B | 13 |
| Next fiscal year (ends Dec 2027) | $1.85 | $1.75 | +5.6% | $3.63B | 13 |
ACHC options: expected move
Options price a move of about ±16.9% (±$5.38) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±15.1% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 74.9% | ±16.9% |
| Dec 18, 2026 | 56 | 59.3% | ±18.8% |
| Jan 15, 2027 | 84 | 54.2% | ±20.5% |
| Mar 19, 2027 | 147 | 55.7% | ±27.6% |
| Jun 17, 2027 | 237 | 58.5% | ±35.9% |
30-day implied volatility 67.6% vs 37.3% realized over the last 30 trading days. Put/call ratio (volume) 0.16. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 31.88 |
|---|---|
| Change | ▲ 1.43% (up) |
| Previous Close | USD 31.43 |
| Open | USD 31.51 |
| Day Range | USD 31.05 – 32.2 |
| 52-Week Range | USD 11.43 – 35.83 |
| Volume | 1,263,788 shares |
| Market Cap | $2.97B |
| Exchange | NMS |
Technical Analysis (ACHC)
Nexqual's technical model rates ACHC "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.85 (neutral) |
| vs SMA50 | Above (USD 28.91) |
| MACD | 0.76 (positive) |
Analyst Ratings (ACHC)
Wall Street analysts rate ACHC "Buy" based on 14 analysts, with a mean price target of USD 33.79 (range USD 17–41), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 33.79 |
| High Target | USD 41 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 8 / 5 / 1 |
Earnings (ACHC)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.46 |
| Revenue Estimate | $877.76M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.38 vs est 0.35 ▲ beat |
| 2026-03-31 | USD 0.37 vs est 0.26 ▲ beat |
| 2025-12-31 | USD 0.07 vs est 0.01 ▲ beat |
| 2025-09-30 | USD 0.72 vs est 0.66 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (ACHC)
| Total Revenue | $3.37B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -0.40% |
| Gross Margin | +41.06% |
| Operating Margin | +10.14% |
| Profit Margin | -33.44% |
| ROE | -41.45% |
| Debt / Equity | 1.18 |
| Current Ratio | 1.57 |
| Total Cash | $171.29M |
| Total Debt | $2.59B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$134.03M (-4.0% of revenue) |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financial Health Score (ACHC)
Nexqual rates Acadia Healthcare Company, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:23 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 41%, operating 10% (last 12 months) |
| Balance Sheet | Mixed — $171M cash and investments vs $2.41B debt (Jun 2026, SEC) |
| Cash Flow | Weak — FCF negative: -$134M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -41%, ROA 3.6% |
Ownership (ACHC)
| Insider Ownership | +1.54% |
|---|---|
| Institutional Ownership | +148.04% |
| Shares Outstanding | 93.10M |
| Float | 91.53M |
| Short % of Float | +37.56% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (ACHC)
Acadia Healthcare Company, Inc. is led by Debra K. Osteen, CEO & Director, per Nexqual as of October 23, 2026 at 09:23 UTC.
| CEO & Director | Debra K. Osteen |
|---|---|
| Senior Vice President of Operations Finance | Timothy Sides |
| Interim Chief Financial Officer | David M. Duckworth |
| Operations Group President | Jeffrey Woods |
| Group President of Specialty Division | Steve Quigley |
Major Backers & Investors (ACHC)
Notable institutional backers of Acadia Healthcare Company, Inc. include Wellington Management, FMR, LLC, Carronade Capital Management, Lp, according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 6.15% |
| FMR, LLC | 5.39% |
| Carronade Capital Management, Lp | 5.12% |
| Morgan Stanley | 4.87% |
| Deerfield Management Company, L.P | 4.85% |
| DME Capital Management, LP | 4.73% |
| Farallon Capital Management LLC | 4.53% |
| Abrams Bison Investments, LLC | 4.47% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 16.07% |
| Vanguard Group | 5.77% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
From Acadia Healthcare Company, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- We have participated in certain relief programs offered through the CARES Act, including receipt of funds relating to the Public Health and Social Services Emergency Fund ("PHSSE Fund"), also known as the Provider Relief Fund, and the American Rescue Plan ("ARP") Rural Payments for Hospitals.
- We are the leading publicly traded pure-play provider of behavioral healthcare services in the U.S.
Partnerships
- We provide residential treatment care through a medical model residential treatment facility, which offers intensive, medically-driven interventions and individualized treatment regimens designed to deal with moderate to high level patient acuity.
- A violation of the Stark Law may result in a denial of payment, required refunds to the Medicare program, the imposition of statutory civil monetary penalties of up to $15,000 for each prohibited claim and up to $100,000 for circumvention schemes, exclusion from government healthcare programs and liability under the False Claims Act.
Legal & Regulatory Risks (Item 1A, quoted)
- We are and in the future could become the subject of governmental investigations, regulatory actions, whistleblower lawsuits and other legal proceedings.
- We are and in the future may become involved in legal proceedings based on negligence or breach of a contractual or statutory duty from service users or their family members or from employees or former employees.
- We could face risks associated with, or arising out of changing laws and regulations, including those involving environmental, health and safety laws and regulations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AVAH | Aveanna Healthcare Holdings Inc | USD 13.32 | ▲ 2.54% |
| GRDN | Guardian Pharmacy Services, Inc | USD 39.59 | ▲ 1.56% |
| BKD | Brookdale Senior Living Inc. | USD 10.19 | ▲ 1.09% |
| MD | Pediatrix Medical Group, Inc. | USD 29.55 | ▲ 5.16% |
| NHC | National HealthCare Corporation | USD 243.07 | ▲ 3.17% |
| ADUS | Addus HomeCare Corporation | USD 122.67 | ▲ 4% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt